Skip to main content
Account

Table 5 Patient characteristics according to intraoperative central or peripheral VA-ECMO use

From: Feasibility of anticoagulation-free peripheral veno-arterial extracorporeal membrane oxygenation in re-do lung transplantation

Variable

central VA-

ECMO(n = 308)

peripheral VA-ECMO (n = 7)

P value

Pre-operative Characteristics

   

Age, years

61.0 [50.0–66.0]

42.0 [38.0–55.0]

0.01

Gender

  

0.13

Male

164 (53.2%)

6 (85.7%)

 

Female

144 (46.8%)

1 (14.3%)

 

BMI, kg/m2

26.5 [21.9–29.5]

22.7 [20.6–24.0]

0.12

BSA, m2

1.9 [1.7-2.0]

1.8 [1.7–1.9]

0.43

Single/Bilateral

  

0.60

Single

44 (14.3%)

0 (0.0%)

 

Bilateral

264 (85.7%)

7 (100.0%)

 

Smoking history

141 (45.8%)

1 (14.3%)

0.13

Hypertension

169 (54.9%)

4 (57.1%)

1.00

Diabetes

88 (28.6%)

3 (42.9%)

0.42

CKD

24 (7.8%)

2 (28.6%)

0.11

Etiology

  

< 0.001

CLAD

0 (0.0%)

7 (100.0%)

 

ILD

148 (48.1%)

0 (0.0%)

 

COPD

36 (11.7%)

0 (0.0%)

 

PAH

29 (9.4%)

0 (0.0%)

 

ARDS

36 (11.7%)

0 (0.0%)

 

Others

59 (19.2%)

0 (0.0%)

 

Laboratory

   

Hemoglobin, g/dL

11.4 [9.3–13.2]

8.4 [7.5–10.7]

0.01

WBC, 1,000/mm3

9.2 [7.1–11.8]

6.2 [2.9–10.6]

0.05

Platelets, 1,000/mm3

238.0 [178.0-304.0]

192.0 [165.0-373.0]

0.99

Sodium, mEq/L

139.0 [137.0-141.0]

142.0 [138.0-143.0]

0.10

Creatinine, mg/dL

0.8 [0.6–0.9]

1.0 [0.7–1.4]

0.02

ALT, U/L

17.0 [11.5–26.5]

13.0 [8.0–23.0]

0.40

AST, U/L

21.0 [17.0–28.0]

23.0 [15.0–29.0]

0.81

Albumin, g/dL

3.9 [3.5–4.2]

4.0 [3.3-4.0]

0.48

Total bilirubin, mg/dL

0.5 [0.4–0.8]

0.3 [0.3–0.5]

0.02

Donor inforomation

   

Age, years

35.0 [26.0–45.0]

39.0 [28.0–45.0]

0.86

Gender

  

0.43

Male

202 (65.6%)

6 (85.7%)

 

Female

106 (34.4%)

1 (14.3%)

 

Cause of death

  

0.54

Anoxia

123 (39.9%)

2 (28.6%)

 

Stroke

80 (26.0%)

1 (14.3%)

 

Head Trauma

101 (32.8%)

4 (57.1%)

 

Other

4 (1.3%)

0 (0.0%)

 

Intra-operative outcomes

   

Operative time (hours)

6.1 [5.1–7.9]

6.8 [6.0-7.9]

0.39

Intra-op blood transfusion; pRBC

280.0 [0.0-560.0]

560.0 [280.0-1400.0]

0.04

Intra-op blood transfusion; FFP

0.0 [0.0-140.0]

140.0 [0.0-560.0]

0.12

Intra-op blood transfusion; Plt

0.0 [0.0-140.0]

0.0 [0.0-280.0]

0.33

Ischemic time (hours)

5.7 [4.9–6.8]

7.4 [7.1–11.4]

0.002

VA ECMO time (hours)

2.8 [2.3–3.3]

3.7 [2.4-4.0]

0.36

Post-operative outcomes

   

de novo DSA

50 (16.2%)

1 (14.3%)

1.00

PGD grade3

57 (18.5%)

1 (14.3%)

1.00

AKI

161 (52.3%)

6 (85.7%)

0.13

Dialysis

50 (16.2%)

2 (28.6%)

0.33

CVA

10 (3.2%)

0 (0.0%)

1.00

Bowel Ischemia

3 (1.0%)

0 (0.0%)

1.00

Digital Ischemia

9 (2.9%)

0 (0.0%)

1.00

DVT

151 (49.0%)

2 (28.6%)

0.45

PE

36 (11.7%)

0 (0.0%)

1.00

Hemothorax

81 (26.3%)

0 (0.0%)

0.20

post ECMO use

55 (17.9%)

0 (0.0%)

0.61

ICU stay

9.0 [5.0-20.5]

10.0 [4.0–24.0]

1.00

Post transplant ventilator

2.0 [1.0-0.5]

2.0 [1.0–7.0]

0.75

Hospital stay

21.0 [13.0–37.0]

18.0 [11.0–9.0]

0.82

Follo-up period (days)

700.0 [330.5-1221.5]

469.0 [199.0-766.0]

0.16

  1. Continuous data are shown as medians and and interquartile ranges (Q1-Q3) for days. CLAD, chronic lung allograft dysfunction; AKI, acute kidney injury; BMI, body mass index; BSA, body surface area; ECMO, extracorporeal membrane oxygenation; LAS, lung allocation score; COPD, chronic obstructive pulmonary disease; CPFE, combined pulmonary fibrosis and emphysema; ILD, interstitial lung disease; ARDS, acute respiratory distress syndome; COVID-19, coronavirus disease 2019; PAH, pulmonary arterial hypertension; WBC, white blood cell; BUN, blood urea nitrogen; INR, international normalized ratio; PRA, panel reactive antibody